NORGESIC FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORGESIC FORTE (NORGESIC FORTE).
Norgesic Forte is a combination of orphenadrine citrate and aspirin (acetylsalicylic acid). Orphenadrine is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties; it acts via blockade of nicotinic acetylcholine receptors at the neuromuscular junction and centrally as a non-competitive antagonist at NMDA receptors, reducing hypertonicity and spasm. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
| Metabolism | Orphenadrine: extensively hepatic, primarily via N-demethylation (CYP2B6, CYP3A4) and hydroxylation; aspirin: rapidly hydrolyzed to salicylic acid by esterases (liver, plasma, erythrocytes), further metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, and oxidation to gentisic acid. |
| Excretion | Renal (70% as unchanged drug and conjugates), fecal (20%), biliary (10%) |
| Half-life | Terminal elimination half-life: 4-6 hours; in elderly or hepatic impairment, half-life may be prolonged up to 12 hours, necessitating dose adjustment. |
| Protein binding | 95% bound; primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 1.0 L/kg; indicates extensive tissue distribution ( > total body water, 0.6 L/kg). |
| Bioavailability | Oral: 80-90% (due to first-pass metabolism); intramuscular: 100% |
| Onset of Action | Oral: 30-60 minutes; intramuscular: 15-30 minutes |
| Duration of Action | Oral: 4-6 hours; intramuscular: 4-8 hours. Clinical note: Duration may be shorter with acute pain and longer with chronic conditions due to accumulation. |
1 tablet orally 3 times daily. Each tablet contains orphenadrine citrate 100 mg and paracetamol 500 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-60 mL/min), reduce frequency to twice daily. No adjustment for mild impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% or extend interval. Use with caution in mild impairment. |
| Pediatric use | Not recommended for children under 12 years. For adolescents 12-18 years, 1 tablet orally twice daily. |
| Geriatric use | Initiate at 1 tablet orally twice daily due to increased risk of anticholinergic effects and renal clearance decline. Monitor for confusion, urinary retention, and falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORGESIC FORTE (NORGESIC FORTE).
| Breastfeeding | Orphenadrine: excreted in breast milk in small amounts (M/P ratio unknown); potential anticholinergic effects in infant. Paracetamol: safe, low excretion (M/P ~1). Caffeine: moderate excretion (M/P ~0.5-1). Avoid use during breastfeeding due to lack of safety data for anticholinergic component. |
| Teratogenic Risk | First trimester: Avoid due to potential skeletal and visceral malformations (animal studies). Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios (NSAID component orphenadrine/paracetamol with NSAID? Note: Norgesic Forte contains orphenadrine, paracetamol, and caffeine; no NSAID clinically; teratogenicity primarily from orphenadrine anticholinergic effects). Limited human data; consider alternative. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to orphenadrine, aspirin, or any component; patients with glaucoma (narrow-angle); gastrointestinal obstruction; achalasia; myasthenia gravis; severe renal or hepatic impairment; bleeding disorders; children or teenagers with viral infections (Reye's syndrome risk); concurrent use of anticholinergic agents; pregnancy (third trimester) due to premature closure of ductus arteriosus; severe hypertension or cardiovascular disease.
| Precautions | Anticholinergic effects: confusion, hallucinations, urinary retention, blurred vision; caution in patients with glaucoma, prostatic hypertrophy, or myasthenia gravis; CYP2B6/CYP3A4 interactions; aspirin-related: increased bleeding risk, Reye's syndrome in children/viral illness, salicylate toxicity; avoid use with alcohol, other NSAIDs, or anticoagulants; use with caution in renal impairment, hepatic impairment, or peptic ulcer disease; may cause drowsiness or dizziness. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, urinary retention, and CNS anticholinergic effects. Fetal monitoring: assess amniotic fluid index if prolonged use (potential oligohydramnios from anticholinergic effects on fetal renal function). |
| Fertility Effects | No known specific effects on fertility. Potential anticholinergic impairment of sexual function in males (erectile dysfunction). Paracetamol at high doses may affect ovarian function; caffeine may reduce fertility at high intake. |